Disruption of sulphated glycosaminoglycans in intestinal inflammation
- PMID:8095623
- DOI: 10.1016/0140-6736(93)90485-y
Disruption of sulphated glycosaminoglycans in intestinal inflammation
Abstract
We have studied the distribution and nature of sulphated glycosaminoglycans (GAGs) within normal and inflamed intestine. There is increasing evidence that these negatively charged polysaccharides, which both regulate the ability of albumin to leave the vasculature and inhibit thrombosis, may be affected by inflammatory cells and their products. We obtained samples of freshly resected intestinal tissue from eight controls, eleven patients with Crohn's disease, and six with ulcerative colitis. Sulphated GAGs were detected by means of a gold-conjugated poly-L-lysine probe, and the tissue density of anionic sites was assessed semiquantitatively by means of a Lennox graticule. In normal intestine there was staining in the vascular endothelium and the subepithelial basal lamina and throughout the extracellular matrix of the lamina propria and submucosa. Tissue from the patients with inflammatory bowel disease showed inflammation macroscopically and on histology. There were profound abnormalities of extracellular matrix GAGs, limited to the mucosa in ulcerative colitis and greatest in the submucosa in Crohn's disease. There was also substantial loss of GAGs from the subepithelial basal lamina in both disorders and from the vascular endothelium in submucosa in Crohn's disease. The extent of local GAG disruption was associated with the distribution of macrophages immunoreactive for tumour necrosis factor alpha and the activation marker RM 3/1. We suggest that inflammatory disruption of vascular and connective tissue GAGs may be an important pathogenetic mechanism, contributing to the leakage of protein and fluid, thrombosis, and tissue remodelling seen in inflammatory bowel disease.
Comment in
- Glycosaminoglycans and the gut.Vantrappen G, Geboes K.Vantrappen G, et al.Lancet. 1993 Mar 20;341(8847):730-1. doi: 10.1016/0140-6736(93)90495-3.Lancet. 1993.PMID:8095632No abstract available.
Similar articles
- Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT.Murch SH, et al.Gut. 1993 Dec;34(12):1705-9. doi: 10.1136/gut.34.12.1705.Gut. 1993.PMID:8031350Free PMC article.
- Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.Griga T, May B, Pfisterer O, Müller KM, Brasch F.Griga T, et al.Hepatogastroenterology. 2002 Jan-Feb;49(43):116-23.Hepatogastroenterology. 2002.PMID:11941933
- Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease.Belmiro CL, Souza HS, Elia CC, Castelo-Branco MT, Silva FR, Machado RL, Pavão MS.Belmiro CL, et al.Int J Colorectal Dis. 2005 Jul;20(4):295-304. doi: 10.1007/s00384-004-0677-2. Epub 2005 Jan 20.Int J Colorectal Dis. 2005.PMID:15660268
- Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.Daig R, Andus T, Aschenbrenner E, Falk W, Schölmerich J, Gross V.Daig R, et al.Gut. 1996 Feb;38(2):216-22. doi: 10.1136/gut.38.2.216.Gut. 1996.PMID:8801200Free PMC article.
- Activation of nuclear factor kappa B in Crohn's disease.Ellis RD, Goodlad JR, Limb GA, Powell JJ, Thompson RP, Punchard NA.Ellis RD, et al.Inflamm Res. 1998 Nov;47(11):440-5. doi: 10.1007/s000110050358.Inflamm Res. 1998.PMID:9865503
Cited by
- Cooperative Transport and Selective Extraction of Sulfates by a Squaramide-Based Ion Pair Receptor: A Case of Adaptable Selectivity.Zaleskaya M, Karbarz M, Wilczek M, Dobrzycki Ł, Romański J.Zaleskaya M, et al.Inorg Chem. 2020 Sep 21;59(18):13749-13759. doi: 10.1021/acs.inorgchem.0c02114. Epub 2020 Sep 4.Inorg Chem. 2020.PMID:32885659Free PMC article.
- Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y, Murch S, Freeze HH.Bode L, et al.J Clin Invest. 2008 Jan;118(1):229-38. doi: 10.1172/JCI32335.J Clin Invest. 2008.PMID:18064305Free PMC article.
- Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy.Day R, Ilyas M, Daszak P, Talbot I, Forbes A.Day R, et al.Dig Dis Sci. 1999 Dec;44(12):2508-15. doi: 10.1023/a:1026647308089.Dig Dis Sci. 1999.PMID:10630505
- Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease.Geleff S, Schoppmann SF, Oberhuber G.Geleff S, et al.Virchows Arch. 2003 Mar;442(3):231-7. doi: 10.1007/s00428-002-0744-4. Epub 2003 Jan 16.Virchows Arch. 2003.PMID:12647212
- Novel Anti-Inflammatory Peptides Based on Chemokine-Glycosaminoglycan Interactions Reduce Leukocyte Migration and Disease Severity in a Model of Rheumatoid Arthritis.McNaughton EF, Eustace AD, King S, Sessions RB, Kay A, Farris M, Broadbridge R, Kehoe O, Kungl AJ, Middleton J.McNaughton EF, et al.J Immunol. 2018 May 1;200(9):3201-3217. doi: 10.4049/jimmunol.1701187. Epub 2018 Mar 23.J Immunol. 2018.PMID:29572348Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical